Farahani Masoumeh, Nirouei Matineh, Moghadam Somaye, Hashemnejad Maryam, Mashak Banafsheh, Alinia Tina, Torabi Sahar
Department of Obstetrics and Gynecology, Alborz University of Medical Sciences, Karaj, Iran.
School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Curr Ther Res Clin Exp. 2023 Apr 6;98:100702. doi: 10.1016/j.curtheres.2023.100702. eCollection 2023.
Cervix ripening and labor induction are common interventions in obstetrics. For optimal maternal health, labor may be induced under certain situations to improve fetal survival outcomes. Labor induction of an unripe cervix can lead to complications; therefore, several approaches can facilitate the ripening process.
This randomized clinical trial was a triple-blind study that involved 84 pregnant nulliparous women enrolled between October 2019 and June 2021 in the labor ward of Kamali Hospital, Karaj, Iran. The pregnant women in the study underwent labor induction and were randomized into 2 groups: 1 group received vaginal dexamethasone and the other group was given a placebo.
There was no significant difference between the groups regarding maternal age, demographic characteristics, and initial Bishop score. The median second Bishop score (6 hours after intervention) was 3.5 in dexamethasone recipients and 3 in placebo recipients ( = 0.48). The median labor latent phase duration was 4 hours in dexamethasone recipients and 5 hours in placebo recipients ( = 0.57).
This randomized clinical trial demonstrated that administering dexamethasone tablets vaginally did not significantly improve cervical Bishop scores. (. 2023; 84:XXX-XXX). ClinicalTrials.gov identifier: NCT05070468.
宫颈成熟和引产是产科常见的干预措施。为了实现最佳的孕产妇健康,在某些情况下可能会进行引产以改善胎儿生存结局。未成熟宫颈引产可能会导致并发症;因此,有几种方法可以促进宫颈成熟过程。
这项随机临床试验是一项三盲研究,纳入了2019年10月至2021年6月期间在伊朗卡拉季卡马利医院产房登记的84名未生育孕妇。研究中的孕妇接受引产,并被随机分为两组:一组接受阴道地塞米松,另一组给予安慰剂。
两组在产妇年龄、人口统计学特征和初始 Bishop 评分方面无显著差异。地塞米松接受者干预后6小时的中位第二次 Bishop 评分为3.5,安慰剂接受者为3(P = 0.48)。地塞米松接受者的中位产程潜伏期为4小时,安慰剂接受者为5小时(P = 0.57)。
这项随机临床试验表明,阴道给予地塞米松片并不能显著提高宫颈 Bishop 评分。(. 2023; 84:XXX - XXX)。ClinicalTrials.gov标识符:NCT05070468。